Graves病與D-二聚體、C反應(yīng)蛋白的相關(guān)性研究
發(fā)布時間：2018-12-11 01:57
【摘要】：研究背景和目的:近年來,有報(bào)道指出,甲狀腺機(jī)能亢進(jìn)癥(甲亢)常伴有凝血功能異常,亞臨床甲狀腺機(jī)能亢進(jìn)癥(亞臨床甲亢)時即存在潛在高凝狀態(tài),臨床上常被忽略。而D-二聚體和C反應(yīng)蛋白是反映機(jī)體內(nèi)高凝狀態(tài)、血栓形成及纖溶活性的重要標(biāo)志物。本研究通過對比Graves病患者與健康體檢者血漿D-二聚體、C反應(yīng)蛋白水平檢測,探討Graves病患者是否存在高凝狀態(tài)及血栓形成傾向。研究方法:選取2014年3月至2015年2月于南昌大學(xué)第二附屬醫(yī)院內(nèi)分泌門診及住院的Graves病初診患者共41例。隨機(jī)抽取同時間段門診健康體檢者41例作為對照組,所有對象均以清晨空腹外周血為采血標(biāo)本,酶聯(lián)免疫法檢測C反應(yīng)蛋白(C reactive protein,CRP)、D-二聚體(D-dimer,D-D)水平。入組病例均排除有嚴(yán)重感染、心腦血管疾病、肝腎疾病、血液系統(tǒng)疾病、糖尿病、近期有服用華法林等抗凝藥物者、妊娠期或哺乳期婦女等病者。數(shù)據(jù)處理采用SPSS 19.0進(jìn)行統(tǒng)計(jì)學(xué)處理,計(jì)量資料檢測數(shù)據(jù)以(sx±)表示,組間比較采用t檢驗(yàn),P0.05為差異有統(tǒng)計(jì)學(xué)意義;相關(guān)性檢驗(yàn)采用Pearson相關(guān)性分析。研究結(jié)果:1、Graves病組D-D濃度為(0.8±0.6)ug/ml,對照組為(0.4±0.2)ug/ml,Graves病組的血漿D-D水平高于正常對照組,兩者的差異具有統(tǒng)計(jì)學(xué)意義(t=4.802,P0.01);Graves病組的血漿CRP水平為(3.5±2.7)mg/l,對照組為(1.6±0.5)mg/l,Graves病組的血漿CRP水平高于正常對照組,兩者的差異具有統(tǒng)計(jì)學(xué)意義(t=4.216,P0.01)。Graves病組與正常對照組促甲狀腺激素(TSH)、血清游離三碘甲腺原氨酸(FT3)、血清游離甲狀腺素(FT4)、甲狀腺球蛋白抗體(TgAb)、甲狀腺過氧化物酶抗體(TPOAb)比較差異均具有統(tǒng)計(jì)學(xué)意義(P0.01)。2、Graves病組血漿CRP、D-D和甲狀腺功能(FT3、FT4、TSH)、甲狀腺自身抗體(TPOAb、TgAb)之間均未見統(tǒng)計(jì)學(xué)相關(guān)性。結(jié)論:Graves病患者D-D、CRP水平均高于正常對照者,表明Graves病患者體內(nèi)血液處于高凝狀態(tài),有血栓形成傾向。Graves病患者血漿CRP和D-二聚體及甲狀腺功能、甲狀腺自身抗體之間均未見統(tǒng)計(jì)學(xué)相關(guān)性。提示甲狀腺機(jī)能亢進(jìn)時,血漿CRP和D-二聚體及甲狀腺功能、甲狀腺自身抗體之間不存在明顯直接關(guān)聯(lián)。
[Abstract]:Background and objective: in recent years, it has been reported that hyperthyroidism (hyperthyroidism) is often accompanied by abnormal coagulation function, while subclinical hyperthyroidism (subclinical hyperthyroidism) has potential hypercoagulability, which is often neglected clinically. D- dimer and C-reactive protein are important markers of hypercoagulability, thrombus formation and fibrinolytic activity. The aim of this study was to compare the levels of plasma D-dimer and C-reactive protein between patients with Graves disease and those with healthy controls to investigate whether the patients with Graves disease had hypercoagulability and thrombosis tendency. Methods: from March 2014 to February 2015, 41 patients with Graves's disease were selected from endocrine outpatient and inpatient department of the second affiliated Hospital of Nanchang University. Forty-one healthy people were randomly selected as control group. All subjects were collected from fasting peripheral blood in the morning. C-reactive protein (C reactive protein,CRP), D-dimer (D-dimer) were detected by enzyme-linked immunosorbent assay (Elisa). D-D) level. All patients were excluded from severe infection, cardiovascular and cerebrovascular diseases, liver and kidney diseases, blood system diseases, diabetes mellitus, recent patients taking warfarin and other anticoagulants, pregnant or lactating women and other diseases. Data processing using SPSS 19.0 for statistical processing, measurement data measured by (sx 鹵), the comparison between groups using t test, P0.05 as the difference was statistically significant; correlation test using Pearson correlation analysis. The results showed that: 1 the D-D level in patients with Graves disease was (0.8 鹵0.6) ug/ml, and (0.4 鹵0.2) ug/ml,Graves disease, which was higher than that in normal controls. The difference between the two was statistically significant (t = 4.802, P0.01). The plasma CRP level in Graves disease group was (3.5 鹵2.7) mg/l, control group was (1.6 鹵0.5) mg/l,Graves disease group, and the plasma CRP level in Graves disease group was significantly higher than that in normal control group (t = 4.216, P < 0.05). P0.01 Serum free triiodothyronine (FT3), serum free thyroxine (FT4) and thyroglobulin antibody (TgAb), (TgAb),) in (TSH), patients with). Graves disease and normal controls There were significant differences in thyroid peroxidase antibody (TPOAb) (P0.01). 2Plasma CRP,D-D, thyroid function (FT3,FT4,TSH), thyroid autoantibody (TPOAb,) in patients with Graves disease. There was no statistical correlation between TgAb. Conclusion: the levels of D-DfCRP in patients with Graves disease are higher than those in normal controls, indicating that the blood of patients with Graves disease is in a state of hypercoagulability and tends to form thrombus. The plasma levels of CRP, D-dimer and thyroid function in patients with Graves disease are higher than those in normal controls. There was no statistical correlation between thyroid autoantibodies. It was suggested that there was no direct correlation between plasma CRP, D-dimer, thyroid function and thyroid autoantibodies in hyperthyroidism.
【學(xué)位授予單位】：南昌大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R581.1
本文編號：2371648
[Abstract]:Background and objective: in recent years, it has been reported that hyperthyroidism (hyperthyroidism) is often accompanied by abnormal coagulation function, while subclinical hyperthyroidism (subclinical hyperthyroidism) has potential hypercoagulability, which is often neglected clinically. D- dimer and C-reactive protein are important markers of hypercoagulability, thrombus formation and fibrinolytic activity. The aim of this study was to compare the levels of plasma D-dimer and C-reactive protein between patients with Graves disease and those with healthy controls to investigate whether the patients with Graves disease had hypercoagulability and thrombosis tendency. Methods: from March 2014 to February 2015, 41 patients with Graves's disease were selected from endocrine outpatient and inpatient department of the second affiliated Hospital of Nanchang University. Forty-one healthy people were randomly selected as control group. All subjects were collected from fasting peripheral blood in the morning. C-reactive protein (C reactive protein,CRP), D-dimer (D-dimer) were detected by enzyme-linked immunosorbent assay (Elisa). D-D) level. All patients were excluded from severe infection, cardiovascular and cerebrovascular diseases, liver and kidney diseases, blood system diseases, diabetes mellitus, recent patients taking warfarin and other anticoagulants, pregnant or lactating women and other diseases. Data processing using SPSS 19.0 for statistical processing, measurement data measured by (sx 鹵), the comparison between groups using t test, P0.05 as the difference was statistically significant; correlation test using Pearson correlation analysis. The results showed that: 1 the D-D level in patients with Graves disease was (0.8 鹵0.6) ug/ml, and (0.4 鹵0.2) ug/ml,Graves disease, which was higher than that in normal controls. The difference between the two was statistically significant (t = 4.802, P0.01). The plasma CRP level in Graves disease group was (3.5 鹵2.7) mg/l, control group was (1.6 鹵0.5) mg/l,Graves disease group, and the plasma CRP level in Graves disease group was significantly higher than that in normal control group (t = 4.216, P < 0.05). P0.01 Serum free triiodothyronine (FT3), serum free thyroxine (FT4) and thyroglobulin antibody (TgAb), (TgAb),) in (TSH), patients with). Graves disease and normal controls There were significant differences in thyroid peroxidase antibody (TPOAb) (P0.01). 2Plasma CRP,D-D, thyroid function (FT3,FT4,TSH), thyroid autoantibody (TPOAb,) in patients with Graves disease. There was no statistical correlation between TgAb. Conclusion: the levels of D-DfCRP in patients with Graves disease are higher than those in normal controls, indicating that the blood of patients with Graves disease is in a state of hypercoagulability and tends to form thrombus. The plasma levels of CRP, D-dimer and thyroid function in patients with Graves disease are higher than those in normal controls. There was no statistical correlation between thyroid autoantibodies. It was suggested that there was no direct correlation between plasma CRP, D-dimer, thyroid function and thyroid autoantibodies in hyperthyroidism.
【學(xué)位授予單位】：南昌大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R581.1
【參考文獻(xiàn)】
相關(guān)期刊論文 前10條
1 鞏建萍;郭雅卿;尹娟;張海容;連雪;謝瑾;楊久宜;;甲狀腺功能亢進(jìn)與動脈粥樣硬化的相關(guān)性研究[J];醫(yī)學(xué)研究與教育;2014年06期
2 吳潔;馬清偉;翟英超;覃西;;甲狀腺瘤、結(jié)節(jié)性甲狀腺腫及甲亢患者凝血功能研究[J];海南醫(yī)學(xué);2013年20期
3 李雅慧;王浩;;甲狀腺機(jī)能亢進(jìn)性心臟病60例臨床分析[J];心臟雜志;2013年05期
4 梁翠格;高冠起;;甲狀腺功能亢進(jìn)癥與凝血功能[J];醫(yī)學(xué)綜述;2012年12期
5 王梅;王金良;;D-二聚體檢測的臨床應(yīng)用進(jìn)展[J];國際檢驗(yàn)醫(yī)學(xué)雜志;2011年01期
6 郭蘭芹;夏建華;黃德亞;;中西醫(yī)結(jié)合治療甲狀腺功能亢進(jìn)40例[J];實(shí)用中醫(yī)內(nèi)科雜志;2010年10期
7 王燕燕;;甲狀腺功能亢進(jìn)癥和缺血性腦卒中[J];國際內(nèi)分泌代謝雜志;2010年04期
8 史海慶;郝明巨;凌欣;李蓉;;甲亢患者血漿Fib、APTT和D-D水平檢測及意義[J];江蘇醫(yī)藥;2010年11期
9 姚東;周愛桃;;老年性甲狀腺功能亢進(jìn)癥的心血管表現(xiàn)67例臨床分析[J];中國醫(yī)學(xué)創(chuàng)新;2009年32期
10 于忠;凌峰;王振東;許軼洲;段徐;;甲狀腺機(jī)能亢進(jìn)癥致緩慢型心律失常16例臨床分析[J];心腦血管病防治;2009年01期
，本文編號：2371648
本文鏈接：http://sikaile.net/yixuelunwen/nfm/2371648.html
最近更新
教材專著
